Definium Therapeutics (NASDAQ:DFTX) Shares Gap Up on Analyst Upgrade

Definium Therapeutics, Inc. (NASDAQ:DFTX) gapped up prior to trading on Wednesday after Robert W. Baird raised their price target on the stock from $37.00 to $57.00. The stock had previously closed at $36.18, but opened at $39.25. Robert W. Baird currently has an outperform rating on the stock. Definium Therapeutics shares last traded at $41.71, with a volume of 3,367,901 shares changing hands.

DFTX has been the subject of a number of other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Tuesday, April 21st. HC Wainwright boosted their price objective on Definium Therapeutics from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Royal Bank Of Canada reissued an “outperform” rating on shares of Definium Therapeutics in a report on Monday. Needham & Company LLC boosted their price objective on shares of Definium Therapeutics from $38.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, Wolfe Research started coverage on Definium Therapeutics in a research note on Monday, February 23rd. They set an “outperform” rating and a $25.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $46.08.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said its Phase 3 Emerge study of DT120 in major depressive disorder met the primary endpoint and all key secondary efficacy endpoints, reinforcing the drug candidate’s clinical value. Definium Therapeutics Announces Positive Topline Results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet (ODT) in Major Depressive Disorder
• Positive Sentiment: Several Wall Street firms lifted price targets after the readout, including Robert W. Baird to $57 and Needham to $50, signaling increased analyst confidence in Definium’s outlook. Definium Therapeutics price target raises
• Positive Sentiment: Lifesci Capital nudged up its 2026 EPS estimates, reflecting slightly better expected profitability despite the company still projecting losses. Definium Therapeutics stock and analyst updates
• Neutral Sentiment: Definium priced an upsized $700 million public offering at $34.00 per share, a move that adds a large amount of capital but also brings dilution for existing shareholders. Definium Therapeutics Announces Pricing of $700 Million Upsized Public Offering
• Negative Sentiment: The planned share sale and subsequent upsized offering may pressure the stock near term because of dilution concerns, even though it strengthens the balance sheet. Definium Therapeutics, Inc. Announces Proposed Public Offering

Hedge Funds Weigh In On Definium Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DFTX. Palumbo Wealth Management LLC increased its stake in Definium Therapeutics by 18.4% during the fourth quarter. Palumbo Wealth Management LLC now owns 39,002 shares of the company’s stock worth $522,000 after acquiring an additional 6,073 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new position in Definium Therapeutics in the 4th quarter worth $117,000. Bay Rivers Group boosted its holdings in Definium Therapeutics by 14.3% in the fourth quarter. Bay Rivers Group now owns 16,001 shares of the company’s stock valued at $214,000 after purchasing an additional 2,000 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Definium Therapeutics in the third quarter worth $107,000. Finally, Caxton Associates LLP bought a new stake in shares of Definium Therapeutics in the 3rd quarter worth about $126,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

Definium Therapeutics Trading Up 17.8%

The company has a market cap of $4.25 billion, a P/E ratio of -17.11 and a beta of 2.37. The business has a fifty day simple moving average of $23.28 and a 200 day simple moving average of $18.75. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69.

Definium Therapeutics (NASDAQ:DFTX) last released its earnings results on Friday, May 8th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.23). Analysts anticipate that Definium Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.